VOYA Investment Management
IKT icon

VOYA Investment Management’s Inhibikase Therapeutics IKT Stock Holding History

VOYA Investment Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.3K Buy
25,286
+8,352
+49% +$14.9K ﹤0.01% 2449
2026
Q1 		$28.4K Buy
16,934
+3,788
+29% +$6.73K ﹤0.01% 2318
2025
Q4 		$26.9K Hold
13,146
– – ﹤0.01% 2388
2025
Q3 		$21.3K Sell
13,146
-5,609
-30% -$9.72K ﹤0.01% 2436
2025
Q2 		$36.6K Buy
+18,755
New +$36.7K ﹤0.01% 2634

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VOYA Investment Management's IKT Position: Q2 2026 in Review

VOYA Investment Management increased its Inhibikase Therapeutics (IKT) stake by 49% in Q2 2026, buying an estimated $14.9K and bringing the position to 25,286 shares worth $51.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

VOYA Investment Management first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • VOYA Investment Management held 25,286 shares of Inhibikase Therapeutics worth $51.3K as of Q2 2026.
  • VOYA Investment Management bought 8,352 Inhibikase Therapeutics shares in Q2 2026, an estimated $14.9K.
  • Inhibikase Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #2449 holding.
  • VOYA Investment Management first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.